ASSET AND EQUITY INTERESTS PURCHASE AGREEMENT Dated as of December 11, 2023 Between NIGHTHAWK BIOSCIENCES, INC. And ELUSYS HOLDINGS INC.
ASSET AND EQUITY INTERESTS PURCHASE AGREEMENT
Dated as of December 11, 2023
Between
And
ELUSYS HOLDINGS INC.
TABLE OF CONTENTS
Page(s)
i
ii
iii
Schedules
Schedule 1.1(b) | Elusys Employees |
Schedule 2.2(b) | Excluded Assets |
Schedule 3.2 | Authority; Noncontravention |
Schedule 3.3 | Good Title; Sufficiency of Assets |
Schedule 3.4 | Brokers and Other Advisors |
iv
Exhibits
Exhibit 1 | Form of Convertible Note |
Exhibit 2.4(b)(i) | Form of Bill of Sale, Assignment and Assumption Agreement |
v
ASSET AND EQUITY INTERESTS PURCHASE AGREEMENT
This Asset and Equity Interests Purchase Agreement (this “Agreement”) dated as of December 11, 2023 is entered into between Elusys Holdings Inc., a Delaware corporation (“Buyer”), and NightHawk Biosciences, Inc., a Delaware corporation (“Seller”). Buyer and Seller are sometimes individually referred to herein as a “Party” and are sometimes collectively referred to herein as the “Parties”. Certain capitalized terms used herein have the meanings ascribed to them in Section 1.1.
RECITALS
WHEREAS, Seller desires to sell all of Seller’s and its Affiliates’ right, title and interest in, to and under the Purchased Assets and transfer the Assumed Liabilities to Buyer, and Buyer wishes to purchase from Seller all of Seller’s and its Affiliates’ right, title and interest in, to and under the Purchased Assets and to assume the Assumed Liabilities, upon the terms and subject to the conditions set forth herein.
WHEREAS, in a separate transaction, Buyer desires to acquire from Seller, and Seller desires to issue to Buyer, a convertible promissory note, upon the terms and subject to the conditions set forth therein, which will be due on the first anniversary of its original issue date, in the aggregate amount of $2,250,000, substantially in the form attached hereto as Exhibit 1 (the “Convertible Note”) reflecting the Note Investment, and for the avoidance of doubt, no consideration attributable to the Note Investment is being paid in connection with the sale of the Purchased Assets and assumption of the Assumed Liabilities.
NOW, THEREFORE, in consideration of the mutual benefits to be derived from this Agreement, and of the representations, warranties, conditions, agreements and promises contained herein, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:
“Action” means any claim, action, suit, arbitration, inquiry, audit, proceeding or governmental investigation.
“Affiliate” of any Person means another Person that directly or indirectly, through one or more intermediaries, Controls, is Controlled by or is under common Control with, such first Person.
“Agreement” has the meaning set forth in the preamble hereof.
“ANTHIM Period” means the period commencing on January 1, 2024 and ending on June 30, 2031.
“Assumed Liabilities” means the Liabilities of the Business (but excluding any Liability arising from the Excluded Assets or the Excluded Taxes), including the Liabilities pursuant to any assumed contracts outstanding as of the Closing Date.
“Assumed Taxes” means any Taxes arising out of, or with respect to, the Purchased Assets for any Post-Closing Tax Period.
“Auditor” has the meaning set forth in Section 2.1(d).
“Bill of Sale, Assignment and Assumption Agreement” has the meaning set forth in Section 2.4(b)(i).
“Books and Records” means all books, records, files, documents and Tax Returns (other than Combined Tax Returns) related to the Purchased Assets (including, the ability to verify the Royalty Payments, the Regulatory Documentation, research and development records, correspondence and, to the extent not originals, true, accurate and complete copies of all files relating to the chain of title, filing, prosecution, issuance, maintenance, enforcement or defense of any Intellectual Property Rights, including any employee and independent contractor Intellectual Property Rights assignment agreement, confidentiality agreement and non-compete agreement, any written correspondence with any Third Party, including any laboratory and engineering notebooks and manufacturing records, procedures, tests, dosage, criteria for patient selection, study protocols and investigators brochures) in all forms in which they are stored or maintained (whether electronic or otherwise), and all data (including Seller Data) and information included or referenced in any of the foregoing, in each case that are owned or otherwise Controlled by or in the possession of Seller or any of its Affiliates.
“Business” means the business conducted by ▇▇▇▇▇▇, including Exploiting all Intellectual Property Rights related to the anthrax antitoxin known as ANTHIM®, and certain related research and development rights and assets, as currently conducted.
“Business Day” means any day other than (a) a Saturday or Sunday or (b) a day on which banking institutions located in New York City are permitted or required by applicable Law to remain closed.
“Buyer” has the meaning set forth in the preamble hereof.
“Buyer Draft Allocation” has the meaning set forth in Section 2.6(a).
“Cash Consideration” has the meaning set forth in Section 2.1(b).
“Closing” has the meaning set forth in Section 2.4(a).
“Closing Date” has the meaning set forth in Section 2.4(a).
“Code” means the Internal Revenue Code of 1986, as amended.
2
“Combined Taxes” means any Taxes which are the subject of a Combined Tax Return.
“Combined Tax Return” means any combined, consolidated or unitary Tax Return which includes Elusys on the one hand, and any of Seller or its Subsidiaries (other than Elusys), on the other.
“Commercially Reasonable Efforts” means the efforts that a pharmaceutical company of similar size would reasonably devote to its own product with similar commercial potential at a similar stage in the research, development or commercialization lifecycle, taking into consideration the anticipated profitability and the cost to develop the product.
“Common Stock” means the common stock, $0.0002 par value per share, of the Seller.
“Consideration” has the meaning set forth in Section 2.1(b)(i).
“Consideration Allocation” has the meaning set forth in Section 2.6(a).
“Contracts” means any loan or credit agreement, bond, debenture, note, mortgage, indenture, lease, supply agreement, license agreement, collaboration agreement, development agreement, distribution agreement, contract research organization agreement or other legally binding contract, agreement, obligation, commitment, arrangement, understanding or instrument, whether oral or written.
“Control” including its various tenses and derivatives (such as “Controlled” and “Controlling”) means (a) when used with respect to any Person, the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such entity, whether through the ownership of voting securities, by Contract or otherwise, (b) when used with respect to any security, the possession, directly or indirectly, of the power to vote, or to direct the voting of, such security or the power to dispose of, or to direct the disposition of, such security and (c) when used with respect to any Intellectual Property Rights, possession of the right, whether directly or indirectly, and whether by ownership, license or otherwise, to assign or grant a license, sublicense or other right to or under such Intellectual Property Rights or to compel another to do so.
“Dollars” or “$” means United States dollars.
“Elusys” means Elusys Therapeutics, Inc., a wholly-owned subsidiary of Seller.
“Elusys Employees” means those persons who are set forth on Schedule 1.1(b).
“Elusys Equity Interests” means the 200,000 shares of common stock, $0.001 par value per share, of Elusys, which are currently issued and outstanding and are held of record by Seller.
“Elusys Merger Agreement” means that certain agreement and plan of merger and reorganization, dated as of December 20, 2021, among the Seller, Heat Acquisition Sub 1, Inc., Elusys Therapeutics, Inc., and Fortis Advisors LLC.
3
“Exchange Act” means the Securities Exchange Act of 1934, as amended.
“Excluded Assets” has the meaning set forth in Section 2.2(b).
“Excluded Taxes” means (i) any Taxes (whether assessed or unassessed) arising out of, or with respect to, the Purchased Assets, the Business, or the Assumed Liabilities for any Pre-Closing Tax Period, (ii) any Taxes of Seller or any of its Affiliates (or for which Seller or any of its respective Affiliates are liable) for any taxable period, including all income Taxes arising in connection with the consummation of the transactions contemplated by this Agreement and the Related Documents and including as a result of the application of “bulk sale” or “bulk transfer” Laws or similar Laws directly as a result of the transactions contemplated by this Agreement and the Related Documents, (iii) any Transfer Taxes that are allocated to Seller pursuant to Section 5.5(a), (iv) Taxes relating to the Excluded Assets for any taxable period, (v) any Taxes of Elusys with respect to any Pre-Closing Tax Period; (vi) any unpaid Taxes of any Person (other than Elusys) under Treasury Regulations Section 1.1502-6 (or any similar provision of Law) that are imposed on Elusys by reason of having been a member of an affiliated, combined, consolidated, unitary or similar group with respect to any Pre-Closing Tax Period; and (vii) any unpaid Taxes of any Person (other than Elusys) for which Elusys is liable as a transferee or successor, by contract or other agreement (other than any such contract or agreement entered into in the ordinary course of business the primary purpose of which is not Tax), or under applicable Law, which Taxes relate to an event or transaction occurring before the Closing.
“Exploit” means to make, have made, import, use, sell, offer for sale, or otherwise dispose of, including to research, develop, register, modify, enhance, improve, manufacture, have manufactured, store, formulate, optimize, export, transport, distribute, commercialize, promote, market, have sold or otherwise dispose of. “Exploiting”, “Exploitation” and other forms of the word “Exploit” shall have correlative meanings.
“FDA” means the U.S. Food and Drug Administration.
“GAAP” means the United States generally accepted accounting principles in effect from time to time.
“Governmental Authority” means any Federal, state, local or foreign government, any court, tribunal, administrative or other governmental agency, department, commission or authority, any Regulatory Authority or any non-governmental self-regulatory agency, commission or authority including without limitation the New York Stock Exchange.
“Governmental Consent” has the meaning set forth in Section 3.2(c).
“IND” means (i) any investigational new drug application relating to a Product filed with the FDA pursuant to 21 C.F.R. Part 312, or any comparable filing made with a Governmental Authority in another country (including the submission to a competent authority of a request for an authorization concerning a clinical trial, as envisaged in Article 9, paragraph 2, of European Directive 2001/20/EC, or any other exemption legitimizing the use of a Product in a clinical
4
investigation), and (ii) all supplements and amendments that may be filed with respect to the foregoing.
“Independent Accounting Firm” means BDO USA, P.A. or a nationally recognized independent accounting firm which has not been engaged by the Sellers or Buyers or any of their respective Affiliates during the three year period ending on the Closing Date that is assigned by the American Arbitration Association.
“Intellectual Property Rights” means all of the following, in each case in any jurisdiction in the world: (a) patents, patent applications, (including in each case any continuation, continuation-in-part, division, renewal, patent term, extension (including any supplemental protection certificate), reexamination or reissue thereof) (collectively, “Patents”); (b) registered and unregistered trademarks, trade dress, trade names, logos, design rights, service marks and any other designation of source or origin, together with the goodwill pertaining to the foregoing, and all applications, registrations and renewals therefor (collectively, “Trademarks”); (c) registered and unregistered copyrights, works of authorship, copyrightable works (published or unpublished) and all applications, registrations and renewals therefor (collectively, “Copyrights”); (d) software, computer programs and applications (whether in source code, object code or other form), algorithms, databases and technology supporting the foregoing, and all error corrections, updates, upgrades, enhancements, translations, modifications, adaptations, further developments and derivative works thereto, and all designs and design documents, technical summaries, documentation (including flow charts, logic diagrams, white papers, manuals, guides and specifications), firmware and middleware associated with the foregoing (collectively, “Software”); and (e) confidential and proprietary technical, scientific, regulatory or other information, designs, ideas, concepts, invention disclosures and inventions (whether patentable or unpatentable and whether or not reduced to practice), research and development, discoveries, results, creations, improvements, know-how, techniques and data (including biological, chemical, pharmacological, toxicological, pharmaceutical, physical and analytical, safety, quality control, manufacturing and preclinical and clinical data), technology, algorithms, procedures, plans, processes, practices, methods, trade secrets, instructions, formulae, formulations, compositions, specifications, marketing, pricing, distribution, cost and sales information, customer and supplier names and lists, tools, materials, apparatus, creations, improvements and other similar materials, and all recordings, graphs, drawings, diagrams, flow charts, models, studies, reports, surveys, analyses and other writings (“Know-How”).
“IRS” means the United States Internal Revenue Service.
“Law” means any federal, state, local or foreign constitution, treaty, law, statute, ordinance, rule or regulation (including any written advisory comments or formal interpretation or guidance thereunder), directive, policy, order, writ, award, decree, injunction, judgment, stay or restraining order of any Governmental Authority, the terms of any permit, and any other ruling or decision of, agreement with or by, or any other requirement of, any Governmental Authority.
“Legal Restraints” has the meaning set forth in Section 6.1(b).
5
“Liabilities” means liabilities, obligations and commitments, whether accrued or fixed, absolute or contingent, known or unknown, determined or determinable, due or to become due, or otherwise.
“Liability Cap” has the meaning set forth in Section 8.1(b).
“Lien” means any lien (statutory or otherwise), security interest, pledge, hypothecation, mortgage, assessment, lease, claim, levy, charge, or any restriction on use or transfer, or other encumbrance.
“Losses” means all losses, damages, liabilities, obligations, deficiencies, fines, interest, judgments, penalties, Taxes, fees, costs or expenses, including reasonable attorneys’ and other professionals’ fees and expenses and other third-party costs of investigation and defense.
“Marketing Authorization Application” means a New Drug Application or Biologics License Application, each as defined in the Act, and any corresponding foreign application, registration or certification granted by a Governmental Authority, including any supplements, amendments or modifications submitted to or required by any Governmental Authority, necessary or reasonably useful to commercialize and market a Product in a particular country or group of countries, but not including pricing and reimbursement approvals.
“Material Adverse Effect” means any change, effect, event, occurrence, state of facts or development which individually or in the aggregate would reasonably be expected to result in, or has resulted in, any change or effect, that is materially adverse to the Business or the Purchased Assets; provided that, for purposes of this definition, none of the following shall be deemed, either alone or in combination, to constitute, and none of the following shall be taken into account in determining whether there has been or will be, a Material Adverse Effect: (i) any change, effect, event, occurrence, state of facts or development relating to the economy in general in the United States or in any other jurisdiction in which the Seller has operations or conducts business, so long as the effects do not disproportionately impact the Business, (ii) any change, effect, event, occurrence, state of facts or development reasonably attributable to conditions affecting the pharmaceutical industry so long as the effects do not disproportionately impact the Business but, in such event, only the incremental disproportionate impact of any such effect will be taken into account in determining whether a Material Adverse Effect has occurred, (iii) any failure by Seller to meet internal projections or forecasts or third party revenue or earnings predictions for any period ending on or after the date of this Agreement (it being understood, however, that any effect causing or contributing to any such failure to meet projections or predictions may constitute a Material Adverse Effect and may be taken into account in determining whether a Material Adverse Effect has occurred); (iv) the execution, delivery, public announcement or performance of this Agreement, (v) earthquakes, hurricanes, tornadoes, natural disasters, epidemics, pandemics, disease outbreaks (including the COVID-19 virus) or global, national or regional political conditions, including hostilities, military actions, political instability, acts of terrorism or war or any escalation or material worsening of any such hostilities, military actions, political instability, acts of terrorism or war existing or underway as of the date hereof (other than any of the foregoing that causes any material damage or destruction
6
to or renders unusable any material Purchased Assets, (vi) any effect that results from any action taken at the prior written request of Buyer or with Buyer’s prior written consent, or (vii) changes in Law or GAAP or any interpretation thereof so long as the effects do not disproportionately impact the Business but, in such event, only the incremental disproportionate impact of any such effect will be taken into account in determining whether a Material Adverse Effect has occurred.
“Note Investment” means the investment by Buyer of $2,250,000 in exchange for and pursuant to the terms of the Convertible Note.
“Order” means any writ, judgment, decree, injunction or similar order, including consent orders, of any Governmental Authority (in each such case whether preliminary or final).
“Outside Date” has the meaning set forth in Section 7.1(b)(i).
“Party” or “Parties” has the meaning set forth in the preamble hereof.
“Permits” means all approvals, authorizations, certificates, filings, franchises, licenses, notices, clearances, registrations and permits of or with all Governmental Authorities, necessary for or related to the Business (and not specifically related to the Seller’s facilities), including all applications for any of the foregoing, together with any renewals, extensions or modifications thereof and additions thereto.
“Permitted Liens” means, collectively, (i) statutory liens for Taxes, assessments and governmental charges not yet due and payable or that are being contested in good faith by appropriate proceedings and for which appropriate reserves have been maintained in accordance with GAAP; and (ii) statutory Liens of landlords and Liens of carriers, warehousemen, mechanics, material men and other Liens imposed by law arising or incurred in the ordinary course of business for amounts that are not yet due and payable and, if required under GAAP, for which appropriate reserves have been created or that are being contested in good faith by appropriate proceedings and that are not resulting from any breach, violation or default by Seller or any of its Affiliates of any Contract or applicable Law.
“Person” means an individual, corporation, partnership, limited liability company, joint venture, association, trust, unincorporated organization or other entity or any Governmental Authority.
“Post-Closing Payment Period” has the meaning set forth in Section 6.5(b).
“Post-Closing Payment Amounts” has the meaning set forth in Section 6.5(b)(ii).
“Post-Closing Tax Period” means any Tax period (or portion thereof) beginning after the Closing Date.
“Pre-Closing Tax Period” means any Tax period (or portion thereof) ending on or before the Closing Date.
7
“Privileged Communications” means any attorney-client communications, confidences, files, work product or other communications related to the Purchased Assets.
“Proxy Statement” has the meaning set forth in Section 5.9(b).
“Purchased Assets” has the meaning set forth in Section 2.2(a).
“Regulatory Authority” means any applicable supra-national, federal, national, regional, state, provincial, or local regulatory agencies, departments, bureaus, commissions, councils, or other government entities regulating or otherwise exercising authority with respect to the development and exploitation of Products.
“Regulatory Authorizations” means, with respect to any jurisdiction, any and all approvals (including pricing and reimbursement approvals), licenses, clearances, registrations or authorizations of any Regulatory Authority necessary or useful for the Exploitation of any compound or (bio)pharmaceutical product in such jurisdiction, including, where applicable, (i) INDs, Marketing Authorization Applications and supplements and amendments thereto, (ii) pre- and post-approval marketing authorizations (including any prerequisite manufacturing approval or authorization related thereto), (iii) labeling approval and (iv) technical, medical and scientific licenses.
“Regulatory Documentation” means any and all (i) applications, filings, submissions, registrations, licenses, permits, notifications, authorizations and approvals (including all Regulatory Authorizations), and non-clinical and clinical study authorization applications or notifications (including all supporting files, writings, data, studies and reports) prepared for submission to a Regulatory Authority or research ethics committee with a view to the obtaining or maintaining of any Regulatory Authorization, including any Investigational Medicinal Product Dossier (IMPD), (ii) correspondence to or with the FDA, European Medicines Agency (EMA) or any other Governmental Authority (including minutes and contact reports relating to any communications with any Governmental Authority), (iii) pharmacovigilance databases, adverse event reports and associated documents, investigations of adverse event reports, and any other records related to safety reporting or data contained or referenced in or supporting any of the foregoing, (iv) manufacturing records or data contained or referenced in or supporting any of the foregoing and (v) nonclinical, clinical and other data contained or referenced in or supporting any of the foregoing.
“Related Documents” means, other than this Agreement, all agreements, certificates and documents signed and delivered by either Party in connection with this Agreement or the transactions contemplated hereby.
“Representatives” means, with respect to any Person, such Person’s directors, officers, managers, employees, counsel, consultants, accountants, financial advisors, lenders and other agents and representatives.
8
“Revenue Derived by Buyer” means the gross dollar amount of payments received by Buyer or any of its Affiliates or any of their successors, assigns, licensees or sublicensees (or any person to whom the Business is sold, assigned or transferred) for all sales of ANTHIM® without any deductions.
“Reviewing Accountant” shall have the meaning set forth in Section 2.6(b).
“Rights Agreement” means the Rights Agreement, dated March 11, 2018, as amended by Amendment No. 1 thereto, dated March 8, 2019, as further amended by Amendment No. 2 thereto, dated March 10, 2020, Amendment No. 3 thereto, dated March 8, 2021, and further amended by Amendment No. 4, dated March 11, 2022, by and between Seller (formerly known as Heat Biologics, Inc.) and Continental Stock Transfer & Trust Company, as rights agent, including as such agreement may be further amended.
“SEC” means the United States Securities and Exchange Commission.
“Securities Act” has the meaning set forth in Section 3.4.
“Seller” has the meaning set forth in the preamble hereof.
“Seller Allocation Notice” has the meaning set forth in Section 2.6(b).
“Seller Board” means the Board of Directors of Seller.
“Seller Indemnified Parties” has the meaning set forth in Section 8.1(e).
“Seller Regulatory Documentation” means any and all Regulatory Documentation, including all Seller Regulatory Authorizations, that is owned by, or otherwise Controlled by, Seller or any of its Affiliates on the Closing Date and that is primarily related to, or is reasonably necessary or useful in the Business.
“Seller’s Charter” means that certain third amended and restated certificate of incorporation of the Seller, as amended, filed with the Secretary of State of the State of Delaware.
“Straddle Period” has the meaning set forth in Section 5.5(b).
“Tax” or “Taxes” means all taxes, assessments, duties, fees or similar charges of any kind whatsoever and wheresoever chargeable (whether or not designated as a tax under applicable Law), in each case in the nature of a tax, including any surcharges, interest, penalties, and additions thereto.
“Tax Return” means all returns (including amended returns), requests for extensions of time, claims for refund, declarations of estimated Tax payments, reports, estimates, information returns and statements, including any schedule or attachment thereto or any related or supporting information with respect to any of the foregoing, filed or required to be filed with any Taxing
9
Authority in connection with the determination, assessment, collection or administration of any Taxes, and any amendment thereof.
“Taxing Authority” means any Governmental Authority or any quasi-governmental body exercising Tax regulatory authority.
“Third Party” means any Person other than: (a) Seller or Buyer or (b) any Affiliates of Seller or Buyer.
“Transfer Taxes” has the meaning set forth in Section 5.5(a).
10
| Affiliates) all of Seller’s (and its Affiliates’) right, title and interest in, to and under all of the Purchased Assets. |
| (i) | on the date of this Agreement, Buyer shall pay to Seller in immediately available funds $500,000 (“Cash Consideration”); |
| (ii) | at the Closing, Buyer shall assume the Assumed Liabilities in accordance with Section 2.3; and |
| (iii) | from and after the Closing, Buyer shall assume all operating costs of Elusys, including the costs incurred after the Closing related to Elusys Employees, consultants, regulatory and research costs. |
| (c) | Royalty Payment. As additional consideration for the Purchased Assets and the other transactions contemplated by this Agreement, on an annual basis, Buyer shall pay to Seller a royalty equal to three percent (3%) of the Revenue Derived by Buyer from the sale of ANTHIM® during the ANTHIM Period, (all such payments being referred to as the “Royalty Payments”); in each case subject to the following additional terms and conditions: |
| (ii) | All Royalty Payments under this Agreement shall be made in US Dollars. Any sales incurred in a currency other than US Dollars shall be converted to the US Dollar equivalent using the then-current standard exchange rate set forth in the Wall Street Journal or as otherwise agreed by the Parties in writing. |
| (iii) | If as of December 31, 2028, Seller shall not have received an aggregate of $5,000,000 in Royalty Payments under this Section 2.1(c), then Buyer shall pay to Seller no later than March 1, 2029, a cash payment equal to |
11
| the difference between $5,000,000 and the aggregate Royalty Payments received by Seller from Buyer pursuant to this Section 2.1(c). |
| (a) | The term “Purchased Assets” means all of Seller’s (and its Affiliates’) right, title and interest in and to the assets delineated below (whether tangible or intangible): |
| (i) | the Elusys Equity Interests; and |
12
| (ii) | exclusive right to use the name “NightHawk” and ownership of any and all trademark, goodwill and other rights the Seller may have in connection with such name. |
| (i) | all cash and cash equivalents of Seller; and |
| (ii) | all Privileged Communications. |
| (b) | Seller Closing Deliverables. At the Closing, Seller shall deliver or cause to be delivered to Buyer: |
| (ii) | a duly completed and accurate IRS Form W-9 from Seller which meets the requirements of a certificate of non-foreign status under Treasury Regulations Section 1.1445-2(b)(2)(v); |
13
| (iii) | all physical or tangible Purchased Assets to a location reasonably designated by Buyer at least five Business Days prior to the Closing; |
| (iv) | a duly executed stock power evidencing all of the Elusys Equity Interests; |
| (v) | the certificate contemplated by Section 6.2(b); and |
| (vi) | access to all Books and Records and Seller Regulatory Documentation that are, (A) Purchased Assets, and (B) in each case, stored in an electronic or digital format in a manner mutually agreed by the Parties. |
| (vii) | any documentation that may be necessary to effect the transfer of the exclusive right to use the name “NightHawk,” and ownership of any and all trademark, goodwill and other rights the Seller may have in connection with such name, to Buyer. |
| (c) | Buyer Closing Deliverables. At the Closing, Buyer shall deliver or cause to be delivered to Seller: |
| (i) | the Bill of Sale, Assignment and Assumption Agreement, duly executed by ▇▇▇▇▇ and/or its applicable Affiliates; and |
| (ii) | the certificate contemplated by Section 6.3(b). |
| (a) | If the assignment or transfer of any asset included in the Purchased Assets or any claim, right or benefit arising thereunder or resulting therefrom, without the consent of a Third Party, would constitute a breach or other contravention of the rights of such Third Party, or would be ineffective with respect to any party to an agreement concerning such asset, claim, right or benefit, then, if requested by Buyer, Seller shall use commercially reasonable efforts, at Buyer’s sole cost and expense, to obtain such consent after the execution of this Agreement until such consent is obtained. For the avoidance of doubt, nothing in this Section 2.5 shall affect any determination as to whether any of the conditions set forth in ARTICLE VI have been satisfied. |
| (b) | Buyer hereby acknowledges the terms and conditions of Section 12.1 of the Elusys Merger Agreement, including without limitation the terms and conditions of Section 12.1(c) thereof. On the date of this Agreement, Seller shall provide written notice to the Stockholders’ Representative (as that term is defined in the Elusys Merger Agreement), in accordance with Section 12.1(c) of the Elusys Merger Agreement, of Seller’s contemplated sale of Elusys pursuant to this Agreement. |
14
15
| notice of the dispute shall promptly notify the other Party in writing of such notice and resolution of the dispute. |
Subject to (a) Schedules 3.2, 3.3, and 3.4 attached hereto (to the extent any such Schedule is numbered to correspond to a representation or warranty, and to the extent that it is reasonably clear from a reading of a disclosure in a Schedule that such disclosure is applicable to another representation or warranty, and provided that the inclusion of any information in the Schedules shall not be deemed to be an admission or acknowledgment, in and of itself, that such information is required by the terms hereof to be disclosed, is material, has resulted in or would result in a Material Adverse Effect, or is outside the ordinary course of business of Seller) and (b) the documents filed with or furnished to the SEC by Seller on or after January 1, 2023 and publicly available on the SEC’s Electronic Data Gathering Analysis and Retrieval system on or before the day that is three (3) Business Days prior to the date of this Agreement (excluding disclosures to the extent predictive, cautionary or forward-looking in nature), Seller represents and warrants to Buyer as set forth in this ARTICLE III.
| (a) | Seller has all requisite corporate power and authority to execute and deliver this Agreement and the Related Documents and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and the Related Documents by Seller and the consummation by Seller of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate action on the part of Seller and no other corporate proceedings on the part of Seller or any of its Affiliates are necessary to authorize this Agreement or the Related Documents). Each of this Agreement and the Related Documents has been duly executed and delivered by ▇▇▇▇▇▇ and, assuming the due authorization, execution and delivery by ▇▇▇▇▇, constitutes a legal, valid and binding obligation of Seller, enforceable against Seller in accordance with its |
16
| terms, subject to bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the rights of creditors generally and the availability of equitable remedies. |
| (b) | The execution and delivery of this Agreement and the Related Documents by Seller do not, and compliance by Seller with the provisions of this Agreement and the Related Documents will not, conflict with, or result in any violation or breach of, or default under (with or without notice or lapse of time, or both), or give rise to a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien (other than a Permitted Lien) in or upon the Purchased Assets under, (i) Seller’s Charter, (ii) any Contract to which Seller or any of its Affiliates is a party or to which any of the Purchased Assets are subject or (iii) any (A) statute, ordinance, rule, regulation or other Law applicable to Seller, any of its Affiliates, the Business or the Purchased Assets or (B) Order applicable to Seller, any of its Affiliates, the Business or the Purchased Assets. |
17
Buyer represents and warrants to Seller as set forth in this ARTICLE IV.
| (a) | Buyer has all requisite corporate power and authority to execute and deliver this Agreement and the Related Documents and to consummate the transactions contemplated by this Agreement. The execution and delivery of this Agreement and the Related Documents by Buyer have been duly authorized by all necessary corporate action on the part of Buyer and no other corporate proceedings on the part of Buyer are necessary to authorize this Agreement, the Related Documents or to consummate the transactions contemplated by this Agreement. Each of this Agreement and the Related Documents has been duly executed and delivered by Buyer (or an Affiliate thereof) and, assuming the due authorization, execution and delivery by Seller, constitutes a legal, valid and binding obligation of Buyer (or an Affiliate thereof), enforceable against Buyer (or an Affiliate thereof) in accordance with its terms, subject to bankruptcy, insolvency, moratorium, reorganization or similar Laws affecting the rights of creditors generally and the availability of equitable remedies. |
| (b) | The execution and delivery of this Agreement and the Related Documents by Buyer do not, and compliance by Buyer with the provisions of this Agreement |
18
| and the Related Documents will not, conflict with, or result in any violation or breach of, or default under (with or without notice or lapse of time, or both), or give rise to a right of, or result in, termination, cancellation or acceleration of any obligation or to the loss of a benefit under, or result in the creation of any Lien in or upon any of the properties or other assets of Buyer under (i) the certificate of incorporation or bylaws of Buyer, (ii) any Contract to which Buyer or to Buyer’s knowledge, Seller any of its or their Affiliates is a party or to which any of its respective properties or other assets is subject, or (iii) any (A) statute, ordinance, rule, regulation or other Law applicable to Buyer or Seller or its properties or other assets or (B) Order applicable to Buyer, Seller any of its or their Affiliates or its properties or other assets, except in the cases of clauses (ii) and (iii), where the conflict, violation, breach, default, termination, cancellation, acceleration or creation of a Lien, individually or in the aggregate, would not reasonably be expected to prevent, materially impede or materially delay the consummation by Buyer of the transactions contemplated by this Agreement (including Buyer’s payment of the Consideration to Seller pursuant to Section 2.1(b)(i)). |
19
Any certificates representing the Securities shall bear the following legend:
THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY.
20
| (a) | From the date of this Agreement until the Closing Date, Seller shall, and shall cause its Affiliates to, (A) maintain and preserve in all respects the Purchased Assets, (B) conduct activities with respect to the Business in the ordinary course |
21
| of business consistent with past practice and (C) comply in all material respects with all Laws and Permits applicable to the Business. |
| (ii) | compromise or settle any Action if the terms of such compromise or settlement would be binding on Buyer or any of its Affiliates, or any Purchased Assets, after the Closing; |
| (v) | fail to maintain true, accurate and complete Books and Records and Docket Files; |
| (vi) | fail to keep in force and effect insurance in respect of the Purchased Assets comparable in amount and scope of coverage to that maintained as of the date of this Agreement; or |
| (vii) | agree to or authorize, or commit to agree to or authorize, in writing or otherwise, any action that would conflict with the obligations set forth in clauses (i) through (vi) above. |
22
23
| (b) | Buyer and Seller hereby acknowledge and agree that notwithstanding any provision of this Agreement, neither Buyer nor any of its Affiliates shall have access to (and each hereby waives any right of access it may otherwise have with respect to) any Privileged Communications, whether or not the Closing occurs. Without limiting the generality of the foregoing, Buyer hereby acknowledges and agrees, upon and after the Closing: (i) neither Buyer nor any of its Affiliates shall be a holder of, or have any right, title or interest to the Privileged Communications, (ii) only Sellers shall hold property rights in the Privileged Communications and shall have the right to waive or modify such property rights and (iii) Sellers shall have no duty whatsoever to reveal or disclose any Privileged Communications to Buyer or any of its Affiliates. |
| (c) | To the extent that any Privileged Communications are disclosed or made available to Seller, the Parties hereby agree (i) that the disclosure, receipt and/or review of such Privileged Communication is entirely inadvertent and shall not waive, modify, limit or impair in any form or fashion the protected nature of the Privileged Communications, (ii) it is their desire, intention and mutual understanding that the sharing of such material is not intended to, and shall not, waive or diminish in any way the confidentiality of such material or its continued protection under the attorney-client privilege, common interest privilege, work product doctrine or other applicable privilege and (iii) Sellers shall have the right in its sole discretion and at any time to require the return and/or destruction of the Privileged Communications. |
24
| (b) | Tax Year and Tax Returns. |
25
| (c) | Allocation of Taxes. In the case of a taxable period that includes, but does not end on, the Closing Date (a “Straddle Period”), (a) Taxes imposed on a periodic basis (such as real, personal and intangible property taxes) for the Pre-Closing Tax Period shall be equal to the amount of such Taxes for the entire Straddle Period multiplied by a fraction, the numerator of which is the number of days during the Straddle Period that are in the Pre-Closing Tax Period and the denominator of which is the number of days in the Straddle Period; and (b) Taxes (other than Taxes described in clause (a)) for any Pre-Closing Tax Period shall be computed as if such taxable period ended as of the close of business on the Closing Date. |
26
| or local (in each case, whether domestic or foreign) Tax Law and pay such amounts over to the appropriate Taxing Authority. The Buyer shall use commercially reasonable efforts to notify Seller reasonably in advance of the date that the applicable payment is to be made to provide such Seller with an opportunity to provide any form or documentation or take such other steps to avoid such withholding. To the extent that amounts are so deducted and withheld and paid over to the appropriate Taxing Authority, such amounts shall be treated for all purposes of this Agreement as having been paid to the party in respect of which such deduction and withholding was made. |
| (g) | Tax Indemnification. |
27
| (h) | Tax Refunds. The Seller shall be entitled to receive any refunds of the Taxes with respect to the Purchased Assets (including, any Taxes of Elusys) or credits received in lieu thereof (including, for the avoidance of doubt, any such refunds that are available to be claimed and for which an election is made to apply such refunds to estimated or other Taxes) plus any interest received with respect thereto from the applicable Tax Authorities for any Pre-Closing Tax Period but only to extent such Taxes were paid by the Seller or by or on behalf of Elusys prior to the Closing Date (any such refund, a “Pre-Closing Refund”). Notwithstanding the foregoing, Pre-Closing Refunds shall not include, and Buyer shall not be required to pay any amounts to Seller in respect thereof, any refunds or credits of Taxes to the extent attributable to any carryback of any Tax asset or attribute that originates in a taxable period (or portion thereof) ending after the Closing Date to a Pre-Closing Tax Period. Any refunds or credits of Taxes for any Straddle Period shall be apportioned between Seller and Buyer in the same manner as the liability for such Taxes is apportioned pursuant to Section 5.5(c). To the extent permitted by Law, any Pre-Closing Refund shall be claimed in cash rather than as a credit against future Tax Liabilities for a Tax period beginning after the Closing Date. Within thirty (30) Business Days, after receipt of any Pre-Closing Refund by the Buyer or any of its Affiliates (or, in the case of a credit obtained in lieu of such refund, no later than thirty (30) Business Days following the filing of the income Tax Return on which such credit is available to be used to offset Tax otherwise payable), the Buyer shall pay over to the Seller the amount of such Pre-Closing Refund, net of the amount of any Taxes imposed on Buyer or any of its Affiliates thereof in connection with the receipt or realization of such Pre-Closing Refund and any reasonable out-of-pocket expenses incurred by the Buyer or any of its Affiliates in obtaining such Pre-Closing Refund (including any income Taxes imposed thereon). |
| (i) | Post-Closing Tax Covenant. Except as required by applicable Law, without the prior written consent of Seller (not to be unreasonably withheld, conditioned or delayed), Buyer shall not nor shall it permit any of its Affiliates to, with respect to the Purchased Assets or Elusys, (i) take any action on the Closing Date after the Closing other than in the ordinary course of business or as otherwise |
28
| contemplated by this Agreement, (ii) make any retroactive Tax election effective for any Pre-Closing Tax Period except as contemplated by Section 5.8, (iii) amend, file or re-file any Tax Return for any Pre-Closing Tax Period, except as contemplated by Section 5.5(b)(iii), or (iv) waive or extend any statute of limitations for the assessment or collection of any Excluded Tax. |
| (a) | If requested by ▇▇▇▇▇, Seller shall participate in making an election under Section 338(h)(10) of the Code and any corresponding election permitted under the applicable Laws of any local, state, or foreign jurisdiction (the “Election”) relative to transactions contemplated by this Agreement. Seller shall cooperate with Buyer to do all things reasonably necessary to make the Election, including but not limited to (i) joining with Buyer in making the Election, (ii) reasonably cooperating with Buyer and taking all actions necessary or appropriate to effect and preserve a timely Election, and (iii) participating in the timely filing of IRS Form 8023 and related or comparable forms for state, local, or foreign Law |
29
| purposes (collectively, the “Section 338(h)(10) Forms”). At Buyer’s request, Seller shall furnish to Buyer such information reasonably requested by Buyer in order to prepare the Section 338(h)(10) Forms, shall review and timely provide comments on such Section 338(h)(10) Forms as provided by Buyer to Seller, and shall, at Buyer’s request, execute such Section 338(h)(10) Forms prepared by Buyer (and agreed upon by the Parties) and deliver such Section 338(h)(10) Forms to Buyer for timely filing by Buyer with the applicable Governmental Authority. |
| (c) | Each Party hereto shall, and shall cause their Affiliates, to treat all payments of the Tax Adjustment as payments of additional Purchase Price for all income Tax purposes (including for purposes of computing the Tax Adjustment). Buyer and Seller shall file all Tax Returns consistently with the Election, the Section 338(h)(10) Forms and the Purchase Price Allocation (as appropriately adjusted) and shall not take any position on any Tax Returns or during the course of any audit or other action or proceeding that is inconsistent with such election, forms or schedule, unless required by a determination of an applicable Governmental Authority that is final. |
30
| (c) | Subject to, and without altering the rights and obligations set forth in, Section 2.6, for a period of 18 months from and after the Closing Date, if either Buyer or Seller becomes aware that any of the Purchased Assets have not been transferred to Buyer or that any of the Excluded Assets have been transferred to Buyer, it shall promptly notify the other and the Parties hereto shall, as promptly as reasonably practicable, use commercially reasonable efforts to ensure such assets are transferred to the correct owner, with any necessary Third Party consents. |
31
| (c) | No Actions. There shall not be pending or threatened in writing any Action brought by any Governmental Authority or any other Person having a reasonable likelihood of prevailing challenging or seeking to restrain or prohibit the consummation of the transactions contemplated by this Agreement. |
| (d) | Elusys Merger Agreement. No less than thirty (30) days have passed since the ▇▇▇▇ ▇▇▇▇▇▇ has given the notice contemplated by Section 2.5(b); provided, however, that the condition set forth in this Section 6.1(d) shall be satisfied immediately upon the waiver by the Stockholders’ Representative (as that term is defined in the Elusys Merger Agreement) of the notice requirement set forth in Section 12.1(c) of the Elusys Merger Agreement. |
| (b) | Performance of Obligations of Seller. Seller shall have performed and complied in all material respects with all of its covenants, agreements and obligations |
32
| contained in this Agreement and required to be performed or complied with on or prior to the Closing Date. Buyer shall have received a certificate signed on behalf of Seller by an authorized executive officer of Seller to such effect with respect to the conditions set forth in Sections 6.2(a) and (b). |
33
| (a) | Buyer shall make the Note Investment pursuant to the terms of the Convertible Note no later than forty (40) days following the date of this Agreement. |
| (b) | From and after the Closing and for so long as any Royalty Payment may occur pursuant to the terms of this Agreement (the “Post-Closing Payment Period”), Buyer hereby agrees that during the Post-Closing Payment Period: |
| (i) | Buyer shall, and shall cause Elusys, as applicable, to (A) use Commercially Reasonable Efforts to maintain, finance, operate and promote ANTHIM®; |
| (ii) | Buyer shall, and shall cause Elusys to, at all times be operated to permit and facilitate the appropriate tracking and calculation of all Royalty Payments amounts that may become due and owing under this Agreement (collectively, the “Post-Closing Payment Amounts”), and Buyer will, and will cause Elusys to, at all times maintain appropriate and necessary Books and Records in accordance with GAAP to evidence and account for, and to pay over, the Post-Closing Payment Amounts and the calculation of such amounts pursuant to this Agreement; and |
| (iii) | Buyer shall not, and shall cause Elusys not to, take any action, or fail to take any action, with the intention to reduce, or with the goal or purpose of reducing, any Post-Closing Payment Amount. Without limiting the foregoing, Buyer shall not take, and shall ensure that Elusys does not take any action or fail to take any action with the goal of (A) delaying the execution of a Contract for the sale or distribution of ANTHIM®, or otherwise delay the occurrence of a Royalty Payment, or (B) decreasing or delaying the Revenues Derived By Buyer, so as to minimize, reduce or eliminate any Post-Closing Payment Amount. |
| (c) | Further, from and after the Closing and for so long as any Royalty Payments may occur pursuant to the terms of this Agreement: |
| (i) | Buyer shall use and shall cause Elusys, as applicable, to use Commercially Reasonable Efforts to maintain, finance, operate and promote ANTHIM®; |
| (ii) | Buyer shall not, and shall cause Elusys not to, directly or indirectly, sell, transfer or assign the Business, Elusys, or the equity of any entity or any material assets used or held for use in the operation of, or otherwise related to, the Business or Elusys (whether by merger, sale of stock, sale of assets or otherwise) unless (i) the purchaser, transferee or assignee of such assets expressly agrees to assume the Royalty Payments and (ii) Seller provides express, written consent to such sale, transfer, or assignment (such consent not to be unreasonably withheld); and |
34
| (iii) | Buyer shall fulfill, and hereby agrees to be bound by, the terms and conditions set forth in the Elusys Merger Agreement with respect the maintenance and operation of the Business (as that term is defined in the Elusys Merger Agreement) (including without limitation Sections 5.2, 5.4, and 12.1 of the Elusys Merger Agreement) for the benefit of the Stockholders (as that term is defined in the Elusys Merger Agreement). |
| (d) | Commencing from and after the first anniversary of the Closing Date, if Seller proposes to register any of its Common Stock under the Securities Act of 1933, as amended, in connection with the public offering of such securities solely for cash, Seller shall, at such time, promptly give Buyer notice of such registration. Buyer shall have the right to request that Seller include the Conversion Shares as part of any other registration of securities filed by Seller (other than in connection with a transaction contemplated by Rule 145(a) promulgated under the Securities Act or pursuant to Form S-8 or any equivalent form); provided, however, that if, solely in connection with any primary underwritten public offering for the account of Seller, the managing underwriter(s) thereof shall, in its or their reasonable discretion, impose a limitation on the number of shares of Common Stock which may be included in the registration statement because, in such underwriter(s)’ judgment, marketing or other factors dictate such limitation is necessary to facilitate public distribution, then Seller shall be obligated to include in such registration statement only such limited portion of the Conversion Shares with respect to which ▇▇▇▇▇ requested inclusion hereunder as the underwriter(s) shall reasonably permit. Upon the request of Buyer given within ten (10) days after such notice is given by Seller, Seller shall, subject to the provisions of this Agreement, use reasonable efforts to cause to be registered all of the Conversion Shares that Buyer has requested to be included in such registration. Seller shall not be required to include any Conversion Shares in any underwritten offering unless the Buyer accepts the terms of such underwriting as agreed between Seller and the underwriter(s) and executes any documents as may be reasonably requested by the underwriter(s). |
| (e) | Seller shall bear all fees and expenses attendant to registering the Conversion Shares pursuant to Section 6.5(d) above, but Buyer shall pay any and all underwriting commissions and the expenses of any legal counsel selected by Buyer to represent it in connection with the sale of the Conversion Shares. In the event of such a proposed registration, Seller shall furnish Buyer with not less than thirty (30) days written notice prior to the proposed date of filing of such registration statement. Such notice to Buyer shall continue to be given for each registration statement filed by Seller until such time as all of the Conversion Shares have been sold by Buyer. Buyer shall exercise the “piggy-back” registration rights provided for herein by giving written notice within ten (10) days of the receipt of Seller’s notice of its intention to file a registration statement. |
35
| (a) | by the written consent of ▇▇▇▇▇ and ▇▇▇▇▇▇; |
| (b) | by either Buyer or Seller, if: |
36
| (b) | Waiver of Claims. IF THE CLOSING OCCURS, BUYER SHALL BE DEEMED TO HAVE WAIVED, AND HEREBY WAIVES, IN FULL ANY BREACH AND CLAIMS ARISING THEREFROM, OF ANY SELLER’S REPRESENTATIONS OR WARRANTIES, WHETHER OR NOT BUYER IS AWARE OF, OR BECOMES AWARE OF, SUCH BREACH BEFORE, AT OR AFTER THE CLOSING. |
37
| LIABILITY CAP IS AN AMOUNT THAT IS REASONABLE IN LIGHT OF THE ANTICIPATED OR ACTUAL HARM CAUSED BY ANY SUCH BREACH CONTEMPLATED ABOVE, THE DIFFICULTIES OF PROOF OF LOSS ARISING FROM SUCH BREACH, AND THE INCONVENIENCE OR INFEASIBILITY OF OTHERWISE OBTAINING AN ADEQUATE REMEDY FOR SUCH BREACH. |
| (d) | Limitation of Damages. NOTWITHSTANDING ANY OTHER PROVISION IN THIS AGREEMENT, NO PARTY SHALL BE LIABLE FOR SPECIAL, PUNITIVE, EXEMPLARY, INCIDENTAL, CONSEQUENTIAL OR INDIRECT DAMAGES (INCLUDING LOSS OF REVENUE, INCOME OR PROFITS BUT ONLY TO THE EXTENT THE SAME ARE NOT DIRECT DAMAGES), DIMINUTION OF VALUE OR LOSS OF BUSINESS REPUTATION OR OPPORTUNITY OF ANY OTHER PARTY OR ANY OF SUCH PARTY’S AFFILIATES, WHETHER BASED ON CONTRACT, TORT, STRICT LIABILITY, OTHER LAW OR OTHERWISE; PROVIDED, HOWEVER, THAT SUCH LIMITATIONS SHALL NOT LIMIT ANY PARTY’S RIGHT TO RECOVER CONTRACT DAMAGES IN CONNECTION WITH THE OTHER PARTY’S FAILURE TO CLOSE IN VIOLATION OF THIS AGREEMENT. |
| (e) | Indemnification. Buyer shall indemnify, defend, and hold harmless Seller and its Affiliates and their respective partners managers, members, directors, officers, shareholders, Representatives, agents, employees, successors and assigns (collectively the “Seller Indemnified Parties”) from and against any and all Losses suffered, sustained or incurred by any Seller Indemnified Party to the extent based upon, relating to, with respect to, arising or resulting from or in connection with, or alleged to result from, arise out of or in connection with any breach, non-performance or non-fulfilment of any covenant, restriction or agreement made, or required to be performed, by Seller in the Elusys Merger Agreement for any alleged action or omission (i) undertaken in connection with this Agreement or the transactions contemplated hereby or (ii) otherwise occurring on and after the date of this Agreement. |
38
if to Buyer, to:
Elusys Holdings Inc.
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
Boca Raton, FL 33487
Attention: ▇▇▇▇ ▇▇▇▇
with copies (which shall not constitute notice) to:
▇▇▇▇▇▇▇▇ ▇▇▇▇ LLP
▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇ ▇▇▇▇▇
New York, New York 10017-6232
Attention: ▇▇▇▇▇ ▇▇▇▇▇▇▇, Esq.
Email: ####
if to Seller, to:
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇
Morrisville, North Carolina 27560
Attention: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
Email: ####
with copies (which shall not constitute notice) to:
Blank Rome LLP
▇▇▇▇ ▇▇▇▇▇▇ ▇▇ ▇▇▇ ▇▇▇▇▇▇▇▇
New York, New York 10020
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇▇, Esq.
Email: ####
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ & ▇▇▇▇▇▇, P.A.
▇▇▇ ▇. ▇▇▇▇ ▇▇., ▇▇▇▇ ▇▇▇▇▇
Wilmington, Delaware 19102
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇, Esq.
Email: ####
39
provided that any notice received at the addressee’s location on any Business Day after 5:00 p.m. (addressee’s local time) shall be deemed to have been received at 9:00 a.m. (addressee’s local time) on the next Business Day.
| (a) | All Actions arising out of or relating to this Agreement shall be heard and determined exclusively in the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware (or in the event, but only in the event, that the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or the United States District Court for the District of Delaware and the appellate court(s) therefrom). The parties hereto hereby (a) irrevocably submit to the exclusive jurisdiction of the Court of Chancery of the State of Delaware and any state appellate court therefrom within the State of Delaware (or in the event, but only in the event, that if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the |
40
| Superior Court of the State of Delaware (Complex Commercial Division) or the United States District Court for the District of Delaware and the appellate court(s) therefrom) for the purpose of any Action arising out of or relating to this Agreement or the transactions brought by any party hereto, (b) irrevocably waive, and agree not to assert by way of motion, defense or otherwise, in any such Action, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution, that the Action is brought in an inconvenient forum, that the venue of the Action is improper, or that this Agreement may not be enforced in or by the above-named courts, and (c) agree that such party will not bring any Action arising out of or relating to this Agreement in any court other than the Court of Chancery of the State of Delaware (or in the event, but only in the event, that if the Court of Chancery of the State of Delaware does not have subject matter jurisdiction, the Superior Court of the State of Delaware (Complex Commercial Division) or the United States District Court for the District of Delaware and the appellate court(s) therefrom). Process in any such Action may be served on any party anywhere in the world, whether within or without the jurisdiction of any such court. Without limiting the foregoing, each party agrees that service of process on such party as provided in Section 8.3 shall be deemed effective service of process on such party. |
41
42
IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their respective officers hereunto duly authorized, all as of the date first written above.
SELLER: | ||
By: | /s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
| ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ |
| Chief Financial Officer |
|
IN WITNESS WHEREOF, the Parties have caused this Agreement to be signed by their respective officers hereunto duly authorized, all as of the date first written above.
BUYER: | ||
ELUSYS HOLDINGS INC. | ||
By: | /s/ ▇▇▇▇▇▇▇ ▇▇▇▇ |
| ▇▇▇▇▇▇▇ ▇▇▇▇ |
| President |
|